Worldwide Molecular Diagnostics Market - Size, Share & Trends Analysis Report (2020 to 2027) - ResearchAndMarkets.com

DUBLIN--()--The "Molecular Diagnostics Market Size, Share & Trends Analysis Report by Product (Instruments, Reagents), by Test Location, by Technology, by Application, by Region, and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics market size is expected to reach USD 18.2 billion by 2027, according to this report registering a CAGR of 9.0% over the forecast period.

Increasing prevalence of infectious diseases such as influenza and human papillomavirus is projected to be the key factor the growth of the market.

In the underdeveloped regions of Africa, increasing instances of infections such as tuberculosis and HIV have been witnessed in the last few years. This is projected to drive the demand for accurate and early diagnostic techniques to curb the spread of these infections.

Rapid technological advancements-leading to accurate results, portability, and cost-effectiveness-are expected to be a high impact rendering driver for this market. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Companies such as Sigma Aldrich Corporation and Qiagen are developing a new range of molecular diagnostic techniques, such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), for the diagnosis of tumors.

Further key findings from the report suggest:

  • Reagents dominated the market in 2019 and is also projected to be the fastest-growing product segment owing to its high adoption in research and clinical settings. Standard reagents also provide efficient and accurate results
  • Instruments such as next generation sequencing platforms and PCR are increasingly preferred by diagnostic institutes and central laboratories as these tests deliver reliable and quick results and are suitable for a number of diagnostic procedures
  • Central laboratories emerged as the leading test location for molecular diagnostics in 2019. This is attributed to the availability of skilled labor and well-established infrastructure
  • Point-of-care is expected to be the fastest-growing segment over the forecast period owing to increase in demand for bedside testing, accuracy of results, and rise in healthcare awareness
  • Infectious diseases were the largest revenue generating segment in 2019 as molecular diagnostics offer clinicians with better substitutes to diagnose numerous infectious pathogens, bacteria, and virus in a short time while producing extremely accurate results

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Molecular Diagnostics Market Variables, Trends & Scope

3.1 Molecular Diagnostics Market Lineage Outlook

3.1.1 Parent market outlook

3.2 Penetration & Growth Prospect Mapping

3.3 Regulatory and Reimbursement Framework

3.4 Market Dynamics

3.4.1 Market driver analysis

3.4.1.1 Increase in geriatric population

3.4.1.2 Introduction of technologically advanced products

3.4.1.3 Increase in demand for point-of-care facilities

3.4.1.4 Growing prevalence of target diseases

3.4.1.5 Increasing external funding for R&D

3.4.2 Market restraint analysis

3.4.2.1 Presence of ambiguous regulatory framework

3.4.2.2 High prices of molecular diagnostics tests

3.5 Molecular Diagnostics Market Analysis Tools

3.5.1 Porter's Five Forces Analysis

3.5.2 SWOT Analysis, By factor (Political & Legal, Economic and Technological)

3.5.3 Major deals & strategic alliances analysis

3.5.3.1 New product launch

3.5.3.2 Mergers and acquisitions

3.5.3.3 Expansion

3.5.3.4 Partnerships

3.5.3.5 Marketing & promotions

3.5.3.6 Market entry strategies

Chapter 4 Molecular Diagnostics Market - Competitive Analysis

4.1 Recent Developments & Impact Analysis, by Key Market Participants

4.1.1 Company/Competition Categorization (Key innovators, Market leaders, Expansion)

4.1.2 Innovators

4.2 Vendor Landscape

4.2.1 List of key distributors

4.2.2 Key company market share analysis, 2019

4.3 Public Companies

4.3.1 Company market position analysis

4.3.2 Competitive Dashboard Analysis

4.4 Private Companies

4.4.1 List of key emerging companies /technology disruptors/innovators

4.4.2 Regional network map

Chapter 5 Products Business Analysis

5.1 Molecular diagnostics market: Products Movement Analysis

5.2 Instruments

5.3 Reagents

5.4 Others

Chapter 6 Test Location Business Analysis

6.1 Molecular diagnostics market: Test Location Movement Analysis

6.2 Point of Care (PoC)

6.3 Self-testing or OTC

6.4 Central Laboratories

Chapter 7 Technology Business Analysis

7.1 Molecular diagnostics market: Technology Movement Analysis

7.2 Polymerase Chain Reaction

7.3 In Situ Hybridization (ISH)

7.4 Isothermal Nucleic Acid Amplification Technology (INAAT)

7.5 Chips and Microarrays

7.6 Mass Spectrometry

7.7 Sequencing

7.8 Transcription Mediated Amplification (TMA)

7.9 Others

Chapter 8 Application Business Analysis

8.1 Molecular diagnostics market: Application Movement Analysis

8.2 Oncology

8.2.1 Oncology market estimates and forecast, 2016 - 2027

8.2.2 Breast cancer

8.2.3 Prostate cancer

8.2.4 Colorectal cancer

8.2.5 Cervical cancer

8.2.6 Kidney cancer

8.2.7 Liver cancer

8.2.8 Blood cancer

8.2.9 Lung cancer

8.2.10 Other cancers

8.3 Pharmacogenomics

8.4 Infectious Diseases

8.5 Genetic Testing

8.6 Neurological Diseases

8.7 Cardiovascular Diseases

8.8 Microbiology

8.9 Others

Chapter 9 Regional Business Analysis

9.1 Molecular diagnostics market: Regional Movement Analysis

9.2 North America

9.3 Europe

9.4 Asia Pacific

9.5 Latin America

9.6 MEA

Chapter 10 Company Profiles

10.1 Market Participation Categorization

10.2 Company Profiles

10.2.1 Abbott

10.2.2 Becton, Dickinson and Company

10.2.3 bioMrieux SA

10.2.4 Bio-Rad Laboratories, Inc.

10.2.5 Agilent Technologies, Inc.

10.2.6 Danaher Corporation

10.2.7 Hologic, Inc. (Gen Probe)

10.2.8 Illumina, Inc.

10.2.9 Johnson & Johnson Services, Inc.

10.2.10 Novartis (Grifols)

10.2.11 Qiagen

10.2.12 F. Hoffmann-La Roche Ltd

10.2.13 Siemens Healthcare Private Limited

10.2.14 Sysmex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/h561j

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900